September 27, 2011

Effect of Hypoxia-Inducible Factor-1α Gene Therapy on Walking Performance in Patients With Intermittent Claudication

Key Points

Key points are not available for this paper at this time.

Abstract

Gene therapy with intramuscular administration of Ad2/HIF-1α/VP16 is not an effective treatment for patients with intermittent claudication. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00117650.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Creager et al. (Tue,) studied this question.

synapsesocial.com/papers/69df2a70d5404a0bea5923bf https://doi.org/https://doi.org/10.1161/circulationaha.110.009407

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch2002 · 1,548 citations
2Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.1995 · 6,216 citations
3Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease1990 · 413 citations
4ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery,⁎⁎AAVS/SVS when Guideline initiated, now merged into SVSSociety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease)2006 · 1,018 citations
5Adenovirus endocytosis2003 · 148 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper